


PRODUCT INFORMATION



Vincamine

Item No. 11763

CAS Registry No.: 1617-90-9
Formal Name: (3 α ,14 β ,16 α)-14,15-dihydro-14-hydroxy-
eburnamenine-14-carboxylic acid, methyl ester
Synonyms: Angiopac, Devincan, Equipur, Minorin, NSC
91998, Novicet, Oxybral, Perval, Sostenil,
Tripervan
MF: C₂₁H₂₆N₂O₃
FW: 354.4
Purity: \geq 98%
UV/Vis.: λ_{max} : 227, 281 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: \geq 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Vincamine is supplied as a crystalline solid. A stock solution may be made by dissolving the vincamine in the solvent of choice. Vincamine is soluble in dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of vincamine in DMF is approximately 0.25 mg/ml.

Vincamine is sparingly soluble in aqueous solutions. To enhance aqueous solubility, dilute the organic solvent solution into aqueous buffers or isotonic saline. If performing biological experiments, ensure the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

Description

Vincamine is an indole alkaloid found in the leaves of *V. minor* and *C. roseus* that is used as a peripheral vasodilator to increase blood flow to the brain.¹ Vincamine contracts excised human cerebrovascular smooth muscle *in vitro* with an EC₅₀ value of 30 μ M and has been explored as a pharmacotherapy to treat cerebral metabolic and vascular diseases.^{2,3}

References

1. Lim, C.C. and James, I.M. The effect of an acute infusion of vincamine and ethyl apovincamate on cerebral blood flow in healthy volunteers. *Br. J. Clin. Pharmacol.* **9(1)**, 100-101 (1980).
2. Young, A.R., Bouloy, M., Boussard, J.-F., *et al.* Direct vascular effects of agents used in the pharmacotherapy of cerebrovascular disease on isolated cerebral vessels. *J. Cereb. Blood Flow Metab.* **1(1)**, 117-128 (1981).
3. Nowicki, J.-P., MacKenzie, E.T., and Spinnewyn, B. Effects of agents used in the pharmacotherapy of cerebrovascular disease on the oxygen consumption of isolated cerebral mitochondria. *J. Cereb. Blood Flow Metab.* **2(1)**, 33-40 (1982).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/08/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM